H.C. Wainwright lowered the firm’s price target on Replimune Group to $48 from $50 and keeps a Buy rating on the shares. The analyst says the updated ARTACUS trial results show a moderate improvement in objective responses versus the interim data readout.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Group put volume heavy and directionally bearish
- Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
- Replimune Group presents updated data on RP2 in uveal melanoma
- Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
- Replimune Group reports Q2 EPS (90c), consensus (86c)
